Medycyna wieku rozwojowego · 2004
[Lipodystrophy in HIV infected children].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Popielska Jolanta, Marczyńska Magdalena
Аннотация
UNLABELLED: Lipodystrophies are rare diseases with abnormal distribution of fat tissue and/or with metabolic changes. The consequence of metabolic abnormalities may be early atherosclerosis or ischaemic heart disease. During the last years lipodystrophy has been more often recognized in HIV infected, antiretroviral treated people. THE AIM was to estimate the prevalence of lipodystrophy in HIV infected children receiving Highly Active Antiretroviral Therapy (HAART).
MATERIAL AND METHODS: 40 children (age 3-16 years) were included in the study. An anamnesis (current complaints and family history) was taken and physical examination was carried out. Laboratory tests included: triglycerides, cholesterol and fractions, glucose.
RESULTS: Medium time of HAART was 4 years. Lipodystrophy was found in 9/40 children. Metabolic abnormalities and clinical manifestations were observed in all children with lipodystrophy. All of them were treated with Zerit, more often with Videx and Kaletra. 5/9 patients with and 5/31 without lipodystrophy had AIDS. Abnormal serum lipid concentrations were observed in 27/31 children without clinical symptoms of lipodystrophy. There was no significant connection with family history and current clinical stage.
CONCLUSIONS: Advance of disease and HAART treatment (especially with Zerit, Videx and Kaletra) increases the risk of this syndrome. Metabolic abnormalities in HAART treated children are frequent, also in children without clinical manifestations of lipodystrophy. Estimated risk of metabolic abnormalities in children should influence the choice of therapeutic schedule or its modification.
MATERIAL AND METHODS: 40 children (age 3-16 years) were included in the study. An anamnesis (current complaints and family history) was taken and physical examination was carried out. Laboratory tests included: triglycerides, cholesterol and fractions, glucose.
RESULTS: Medium time of HAART was 4 years. Lipodystrophy was found in 9/40 children. Metabolic abnormalities and clinical manifestations were observed in all children with lipodystrophy. All of them were treated with Zerit, more often with Videx and Kaletra. 5/9 patients with and 5/31 without lipodystrophy had AIDS. Abnormal serum lipid concentrations were observed in 27/31 children without clinical symptoms of lipodystrophy. There was no significant connection with family history and current clinical stage.
CONCLUSIONS: Advance of disease and HAART treatment (especially with Zerit, Videx and Kaletra) increases the risk of this syndrome. Metabolic abnormalities in HAART treated children are frequent, also in children without clinical manifestations of lipodystrophy. Estimated risk of metabolic abnormalities in children should influence the choice of therapeutic schedule or its modification.